These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 17126522)

  • 1. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
    Pelosi E; Deandreis D
    Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective comparative study of contrast-enhanced CT, contrast-enhanced MRI and 18F-FDG PET/CT in the preoperative staging of colorectal cancer patients.
    Guney IB; Teke Z; Kucuker KA; Yalav O
    Ann Ital Chir; 2020; 91():658-667. PubMed ID: 32213686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fluorine-18-2-deoxy-2-fluoro-D-glucose positron emission tomography in colorectal cancer].
    Tang G; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Feb; 22(1):193-6, 201. PubMed ID: 15762148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography in colorectal cancer.
    Flamen P
    Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
    Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
    Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
    Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Established, emerging and future roles of PET/CT in the management of colorectal cancer.
    Herbertson RA; Scarsbrook AF; Lee ST; Tebbutt N; Scott AM
    Clin Radiol; 2009 Mar; 64(3):225-37. PubMed ID: 19185652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
    Wiering B; Ruers TJ; Oyen WJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of positron emission tomography in the management of recurrent colorectal cancer: a review.
    Watson AJ; Lolohea S; Robertson GM; Frizelle FA
    Dis Colon Rectum; 2007 Jan; 50(1):102-14. PubMed ID: 17115340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET and PET/CT for colorectal cancer.
    Delbeke D; Martin WH
    Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
    Donswijk ML; Hess S; Mulders T; Lam MG
    PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.
    Kim JH; Czernin J; Allen-Auerbach MS; Halpern BS; Fueger BJ; Hecht JR; Ratib O; Phelps ME; Weber WA
    J Nucl Med; 2005 Apr; 46(4):587-95. PubMed ID: 15809480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET in colorectal cancer.
    de Geus-Oei LF; Ruers TJ; Punt CJ; Leer JW; Corstens FH; Oyen WJ
    Cancer Imaging; 2006 Oct; 6(Spec No A):S71-81. PubMed ID: 17114081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.